Physician profile
Michael A Bianco
NPI 1740212885
$5,532.52
in general payments reported to CMS, 2019-2025
36 companies · $35.41 in 2025
The $35.41 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,958 · 2020: $1,205 · 2021: $1,868 · 2022: $162 · 2023: $171 · 2024: $134 · 2025: $35.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,023.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.34 | 2019-2021 | |
| Amgen INC. | $356.87 | 2019-2021 | |
| Abbvie INC. | $353.68 | 2021-2022 | |
| Cook Medical LLC | $340.41 | 2023-2025 | Zenith Spiral-Z, Lunderquist, Amplatz |
| Lilly USA, LLC | $325.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $319.77 | 2019-2021 | |
| Glaxosmithkline, LLC. | $294.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.37 | 2019-2021 | |
| Astellas Pharma US INC | $174.27 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $153.67 | 2021 | |
| Amarin Pharma, INC. | $147.64 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.25 | 2020-2021 | |
| Integra Lifesciences Corporation | $143.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $108.90 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $78.98 | 2019-2021 | |
| Allergan, INC. | $76.96 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $67.97 | 2019-2020 | |
| Clarus Therapeutics INC. | $59.87 | 2021 | |
| Endo Pharmaceuticals INC. | $58.77 | 2019-2021 | |
| Genentech USA, INC. | $56.07 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $52.63 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $38.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.30 | 2021 | |
| Daiichi Sankyo INC. | $35.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.53 | 2019-2020 | |
| Eisai INC. | $32.32 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $31.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.11 | 2021 | |
| Amneal Pharmaceuticals LLC | $23.12 | 2021 | |
| Biogen, INC. | $19.54 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.58 | 2020 | |
| Mannkind Corporation | $17.58 | 2019 | |
| Ucb, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.